Brokerages Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $233.42

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $241.21.

BGNE has been the topic of several analyst reports. Bank of America reduced their price target on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Citigroup raised their target price on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. JMP Securities started coverage on BeiGene in a report on Wednesday. They set a “market outperform” rating and a $288.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th.

Insider Activity

In other news, SVP Chan Henry Lee sold 834 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $160.57, for a total value of $133,915.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total value of $133,915.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Xiaobin Wu sold 4,500 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total value of $900,630.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,210 shares of company stock valued at $3,270,351. 7.43% of the stock is currently owned by corporate insiders.

Institutional Trading of BeiGene

Several institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new position in BeiGene during the 1st quarter worth approximately $50,000. Benjamin F. Edwards & Company Inc. increased its position in shares of BeiGene by 51.5% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock worth $128,000 after buying an additional 279 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new position in BeiGene during the fourth quarter worth $183,000. Acadian Asset Management LLC lifted its holdings in BeiGene by 204.1% in the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after buying an additional 849 shares during the period. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in BeiGene during the first quarter valued at $209,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Stock Performance

NASDAQ:BGNE opened at $201.99 on Monday. The company has a market cap of $19.57 billion, a price-to-earnings ratio of -26.68 and a beta of 0.61. BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $215.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. The stock has a fifty day moving average price of $182.24 and a 200-day moving average price of $164.45.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. During the same quarter in the prior year, the business posted ($3.64) earnings per share. BeiGene’s revenue was up 56.1% compared to the same quarter last year. As a group, equities analysts anticipate that BeiGene will post -5.13 EPS for the current fiscal year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.